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OBJECTIVE—Chronic activation of the nuclear factor-B
(NF-B) in white adipose tissue leads to increased production of
pro-inflammatory cytokines, which are involved in the develop-
ment of insulin resistance. It is presently unknown whether
peroxisome proliferator–activated receptor (PPAR) / activa-
tion prevents inflammation in adipocytes.
RESEARCH DESIGN AND METHODS AND RESULTS—
First, we examined whether the PPAR/ agonist GW501516
prevents lipopolysaccharide (LPS)-induced cytokine production
in differentiated 3T3-L1 adipocytes. Treatment with GW501516
blocked LPS-induced IL-6 expression and secretion by adipo-
cytes and the subsequent activation of the signal transducer and
activator of transcription 3 (STAT3)–Suppressor of cytokine
signaling 3 (SOCS3) pathway. This effect was associated with the
capacity of GW501516 to impede LPS-induced NF-B activation.
Second, in in vivo studies, white adipose tissue from Zucker
diabetic fatty (ZDF) rats, compared with that of lean rats,
showed reduced PPAR/ expression and PPAR DNA-binding
activity, which was accompanied by enhanced IL-6 expression
and NF-B DNA-binding activity. Furthermore, IL-6 expression
and NF-B DNA-binding activity was higher in white adipose
tissue from PPAR/-null mice than in wild-type mice. Because
mitogen-activated protein kinase–extracellular signal–related ki-
nase (ERK)1/2 (MEK1/2) is involved in LPS-induced NF-B
activation in adipocytes, we explored whether PPAR/ pre-
vented NF-B activation by inhibiting this pathway. Interestingly,
GW501516 prevented ERK1/2 phosphorylation by LPS. Further-
more, white adipose tissue from animal showing constitutively
increased NF-B activity, such as ZDF rats and PPAR/-null
mice, also showed enhanced phospho-ERK1/2 levels.
CONCLUSIONS—These findings indicate that activation of
PPAR/ inhibits enhanced cytokine production in adipocytes by
preventing NF-B activation via ERK1/2, an effect that may help
prevent insulin resistance. Diabetes 57:2149–2157, 2008
A ccumulating evidence implicates a low-gradechronic systemic inflammatory response to nu-trient excess as a key mechanism that linksobesity to metabolic disorders, including insu-
lin resistance and cardiovascular disease (1). Thus, models
of diet-induced and genetic obesity show increased adi-
pose tissue expression and content of pro-inflammatory
cytokines (such as tumor necrosis factor- [TNF-], inter-
leukin [IL] 1, monocyte chemo-attractant protein-1 [MCP-1],
and IL-6) (2–4). Of these cytokines, IL-6 correlates most
strongly with insulin resistance and type 2 diabetes (5–7);
its plasma levels are increased two- to threefold in patients
with obesity and type 2 diabetes compared with lean
control subjects (6). At the cellular level, insulin resistance
and enhanced expression of these cytokines by adipose
tissue during obesity and also under a high-fat diet have
been linked to activation of the pro-inflammatory tran-
scription factor nuclear factor-B (NF-B) (4). This nu-
clear factor is activated by surface proteins that recognize
foreign substances, the so-called pattern recognition re-
ceptors, such as toll-like receptor-4 (TLR4). This receptor
is expressed on virtually all human cells and binds a wide
spectrum of exogenous and endogenous ligands, including
bacterial lipopolysaccharide (LPS) (8). In the presence of
LPS, the TLR4 complex (including CD-14 and an accessory
protein, MD-2), recruits the adaptor protein, myeloid dif-
ferentiation factor-88, which in turn recruits IL-1 receptor–
associated kinase, leading to NF-B activation and
enhanced expression of several inflammatory mediators
(including IL-6 and MCP-1). Of note, NF-B activation by
LPS requires mitogen-activated protein kinase (MAPK)–
extracellular signal–related kinase (ERK)1/2 (MEK1/2) ac-
tivation, because inhibition of this pathway reduces LPS-
induced cytokine production in adipocytes (9).
Recent evidence suggests that inflammatory processes
induced by obesity and high-fat diet cause systemic insulin
resistance via a mechanism involving TLR4 (10). For
instance, saturated free fatty acids (FFAs) activate TLR4-
mediated inflammatory signaling in adipocytes and macro-
phages, and this effect is blunted in the absence of this
receptor (10). These observations indicate that enhanced
adipose tissue lipolysis observed in insulin-resistant states
may release the endogenous ligand for TLR4 to induce
inflammation (11). In addition, it has been demonstrated
that high-fat diets augment plasma LPS to a concentration
sufficient to increase body weight, fasting glycemia and
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inflammation (12). Furthermore, LPS receptor–deleted
mice (CD14 mutants) are hypersensitive to insulin, and the
development of insulin resistance, obesity, and diabetes in
this animal model is delayed in response to a high-fat diet
(12).
In recent years, peroxisome proliferator–activated re-
ceptor / (PPAR/) activation has been proposed as a
potential treatment for insulin resistance (13). PPARs are
members of the nuclear receptor superfamily of ligand-
inducible transcription factors. They form heterodimers
with retinoid X receptors (RXRs) and bind to consensus
DNA sites composed of direct repeats of hexameric DNA
sequences separated by 1 bp (DR1) (14). Ligand binding
induces a conformational change in PPAR-RXR com-
plexes, thereby releasing corepressors in exchange for
coactivators, which leads to the recruitment of the basal
transcription machinery and enhanced gene expression. In
addition, PPARs may suppress inflammation through di-
verse mechanisms, such as reduced release of inflamma-
tory factors or stabilization of repressive complexes at
inflammatory gene promoters (15–18). Of the three PPAR
isotypes found in mammals, PPAR (NR1C1) (19) and
PPAR (NR1C3) are the targets for hypolipidemic (fi-
brates) and antidiabetic (thiazolidinediones) drugs, re-
spectively. Finally, activation of the third isotype,
PPAR/ (NR1C2) by high-affinity ligands (including
GW501516) enhances fatty acid catabolism in adipose
tissue and skeletal muscle, thereby delaying weight gain
(rev. in 13). However, there is no information available on
whether PPAR/ ligands prevent inflammation in adipo-
cytes. Here, we examined whether PPAR/ activation by
GW501516 prevents LPS-induced inflammation in adipo-
cytes. We found that this drug prevented LPS-induced IL-6
expression and secretion by adipocytes. This effect was
associated with the capacity of the PPAR/ ligand to
prevent LPS-induced NF-B activation. Consistent with
the role of PPAR/ in blocking NF-B–induced IL-6
expression, a genetic model of obesity and insulin resis-
tance, the ZDF rat, showed reduced PPAR/ expression
and DNA-binding activity and enhanced IL-6 expression
and NF-B DNA-binding activity in white adipose tissue.
Likewise, IL-6 expression and NF-B DNA-binding activity
was higher in this tissue in PPAR/-null mice than in
wild-type mice. Because MEK1/2 is involved in NF-B
activation in adipocytes (9), we explored whether
PPAR/ blocked NF-B activation by inhibiting this path-
way. In agreement with this possibility, GW501516 pre-
vented ERK1/2 phosphorylation by LPS. In contrast,
animal models showing increased NF-B activity in white
adipose tissue, the ZDF rat and the PPAR/-null mice,
showed enhanced phospho-ERK1/2 levels. Overall, on the
basis of our findings, we propose that PPAR/ activation
be considered a molecular target to prevent inflammation
of adipose tissue and the metabolic alterations associated
with this process, such as insulin resistance.
RESEARCH DESIGN AND METHODS
The PPAR/ ligand GW501516 was from Biomol Research Labs (Plymouth
Meeting, PA). Other chemicals were from Sigma (St. Louis, MO).
Cell culture. 3T3-L1 preadipocytes (American Type Culture Collection) were
grown to confluence in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% bovine calf serum. Differentiation of the 3T3-L1 cells was
induced 2 days after confluence (day 0) in DMEM containing 10% fetal bovine
serum, 500 mol/l methylisobutylxanthine, 0.25 mol/l dexamethasone, and
10 g/ml insulin for 48 h. The cells were then incubated in 10% FBS/DMEM
with insulin for 8 days. Medium was changed every 2 days. Fat droplets were
observed in 90% of cells after day 10. Adipocytes were then incubated for
96 h with 0.5 mol/l GW501516 and then with 100 ng/ml LPS for either 1 or
24 h. After the incubation, RNA, total proteins, and nuclear extracts were
extracted from adipocytes as described below. Inhibitors were added 30 min
before the incubation with LPS. Culture supernatants were collected, and the
secretion of IL-6 was assessed by ELISA (Amersham Biosciences, Little
Chalfont, U.K.).
Animals. Male obese ZDF rats (ZDF/Gmi, fa/fa) and lean litter mates (fa/ or
/) were used. Both strains were maintained under standard light-dark
cycle (12-h light/dark cycle) and temperature (21 	 1°C) and fed with the
Purina 5008 chow. Epidydimal white adipose tissue was rapidly removed,
frozen in liquid nitrogen, and stored at 
80°C. Blood samples were collected
in EDTA tubes, and plasma was obtained by centrifugation at 2,200  g for 10
min at 4°C. Plasma glucose (Sigma), triglycerides (Sigma), and nonesterified
fatty acids (Wako, Germany) levels were determined with a colorimetric test.
Insulin (Amersham Biosciences) was determined by radioimmunoassay. All
procedures were conducted in accordance with the principles and guidelines
established by the University of Barcelona Bioethics Committee, as stated in
Law 5/1995, 21st July, passed by the Generalitat de Catalunya. The generation
of PPAR/-null mice has been described previously (20).
Measurements of mRNA. Levels of mRNA were assessed by the RT-PCR as
previously described (21). Total RNA was isolated using the Ultraspec reagent
(Biotecx, Houston, TX). The total RNA isolated by this method is nondegraded
and free of protein and DNA contamination. The sequences of the sense and
antisense primers used for amplification were: IL-6, 5-TCCAGCCAGTTGC
CTTCTTGG-3 and 5-TCTGACAGTGCATCATCGCTG-3; Mcp-1, 5-GGGCCT
GTTGTTCACAGTTGC-3 and 5-GGGACACCTGCTGCTGGTGAT-3; Pdk-4,
5-AGGTCGAGCTGTTCTCCCGCT-3 and 5-GCGGTCAGGCAGGATGTCAAT-
3; Cpt-I, 5-TTCACTGTGACCCCAGACGGG-3 and 5-AATGGACCAGCCCC
ATGGAGA-3; Ppar/ 5-GAGGAAGTGGCCACGGGTGAC-3 and 5-CCACC
TGAGGCCCCATCACAG-3; Socs-3, 5-TTTTCGCTGCAGAGTGACCCC-3 and
5-TGGAGGAGAGAGGTCGGCTCA-3; and adenosyl phosphoribosyl trans-
ferase (Aprt), 5-GCCTCTTGGCCAGTCACCTGA-3 and 5-CCAGGCTCACA-
CACTCCACCA-3. Amplification of each gene yielded a single band of the
expected size (IL-6, 229 bp; Mcp-1, 157 bp; Pdk-4, 167 bp; Cpt-I, 222 bp;
Ppar/, 151 bp; Socs-3, 250 bp; and Aprt, 329 bp). Preliminary experiments
were carried out with various amounts of cDNA to determine nonsaturating
conditions of PCR amplification for all the genes studied. Therefore, under
these conditions, relative quantification of mRNA was assessed by the RT-PCR
method used in this study (22). Radioactive bands were quantified by
video-densitometric scanning (Vilbert Lourmat imaging). The results for the
expression of specific mRNAs are always presented relative to the expression
of the control gene (Aprt).
Isolation of nuclear extracts. Nuclear extracts were isolated as previously
described (21). Cells were scraped into 1.5 ml cold PBS, pelleted for 10 s, and
resuspended in 400 l cold buffer A (10 mmol/l HEPES, pH 7.9, at 4°C, 1.5
mmol/l MgCl2, 10 mmol/l KCl, 0.5 mmol/l dithiothreitol [DTT], 0.2 mmol/l
phenylmethylsulfonyl fluoride [PMSF], and 5 g/ml aprotinin) by flicking the
tube. Cells were allowed to swell on ice for 10 min and then vortexed for 10 s.
Samples were then centrifuged for 10 s, and the supernatant fraction was
discarded. Pellets were resuspended in 50 l cold buffer C (20 mmol/l
HEPES-KOH, pH 7.9, at 4°C, 25% glycerol, 420 mmol/l NaCl, 1.5 mmol/l MgCl2,
0.2 mmol/l EDTA, 0.5 mmol/l DTT, 0.2 mmol/l PMSF, 5 g/ml aprotinin, and 2
g/ml leupeptin) and incubated on ice for 20 min for high-salt extraction.
Cellular debris was removed by centrifugation for 2 min at 4°C and the
supernatant fraction (containing DNA-binding proteins) was stored at 
80°C.
Nuclear extract concentration was determined by the Bradford method.
Electrophoretic mobility shift assay. Electrophoretic mobility shift assay
(EMSA) was performed using double-stranded oligonucleotides (Promega,
Madison, WI) for the consensus binding site of the NF-B nucleotide (5-
AGTTGAGGGGACTTTCCCAGGC-3) and PPAR (5-CAAAACTAGGTCAAAG
GTCA-3). Oligonucleotides were labeled in the following reaction: 2 l
oligonucleotide (1.75 pmol/l), 2 l 5 kinase buffer, 1 l T4 polynucleotide
kinase (10 units/l), and 2.5 l [-32P]ATP (3,000 Ci/mmol at 10 mCi/ml)
incubated at 37°C for 1 h. The reaction was stopped by adding 90 l
Tris-EDTA buffer (10 mmol/l Tris-HCl, pH 7.4, and 1 mmol/l EDTA). To
separate the labeled probe from the unbound ATP, the reaction mixture was
eluted in a Nick column (Amersham) following the manufacturer’s instruc-
tions. Eight micrograms of crude nuclear protein was incubated for 10 min on
ice in binding buffer (10 mmol/l Tris-HCl, pH 8.0, 25 mmol/l KCl, 0.5 mmol/l
DTT, 0.1 mmol/l EDTA, pH 8.0, 5% glycerol, 5 mg/ml BSA, and 50 g/ml
poly(dI-dC)), in a final volume of 15 l. Labeled probe (60,000 cpm) was
added, and the reaction was incubated for 15 min at 4°C (NF-B) or room
temperature (peroxisome proliferator response element). Where indicated,
specific competitor oligonucleotide was added before the labeled probe
and incubated for 10 min on ice. p65 antibody was added 15 min before
incubation with the labeled probe at 4°C. Protein-DNA complexes were
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resolved by electrophoresis at 4°C on a 5% acrylamide gel and subjected to
autoradiography.
Immunoblotting. To obtain total protein, cells and adipose tissue were
homogenized in cold lysis buffer (5 mmol/l Tris-HCl, pH 7.4, 1 mmol/l EDTA,
0.1 mmol/l PMSF, 1 mmol/l sodium orthovanadate, and 5.4 g/ml aprotinin).
The homogenate was centrifuged at 16,700  g for 30 min at 4°C. Protein
concentration was measured by the Bradford method. Proteins (30 g) were
resolved by SDS-PAGE on 10% separation gels and transferred to Immobilon
polyvinylidene difluoride membranes (Millipore, Bedford, MA). Western blot
analysis was performed using antibodies against total and phospho-ERK1/2
(Cell Signaling) and total (Santa Cruz) and phospho-STAT3 (Tyr705) and
Ser727) (Cell Signaling). Detection was achieved using the EZ-ECL chemilu-
minescence kit (Amersham). Size of detected proteins was estimated using
protein molecular-mass standards (Invitrogen, Barcelona, Spain).
Statistical analyses. Results are expressed as means 	 SD of five separate
experiments. Significant differences were established by Student’s t test or
one-way ANOVA, according to the number of groups compared, using the
GraphPad Instat program, v2.03 (GraphPad Software, San Diego, CA). In the
latter case, when significant variations were found, the Tukey-Kramer multiple
comparisons test was applied. Differences were considered significant at P 
0.05.
RESULTS
PPAR/ activation prevents LPS-induced IL-6 ex-
pression and secretion in 3T3-L1 adipocytes. Differ-
entiated 3T3-L1 adipocytes were exposed for 24 h to 0.5
mol/l GW501516, a selective ligand for PPAR/ with an
apparent Kd value of 1 nmol/l and 1,000-fold higher affinity
toward PPAR/ than PPAR and PPAR (23). Under
these conditions, we evaluated the expression of two
well-known PPAR/-target genes, pyruvate dehydroge-
nase kinase 4 (Pdk4) and carnitine palmitoyltransferase 1
(Cpt-I) (24). Ligand treatment for 24 h caused a slight
increase in the mRNA levels of both Pdk4 (100%, P 0.01)
and Cpt-I (45%, P  0.05) (Fig. 1A). When adipocytes were
treated for 96 h with 0.5 mol/l GW501516, a greater
increase was observed in the transcript levels of Pdk4
(170%, P  0.001) and Cpt-I (300%, P  0.01) (Fig. 1B).
Therefore, we selected this longer exposure to the
PPAR/ ligand in further experiments. No changes were
observed either in the expression of well-known PPAR-
target genes (i.e., Ob: data not shown), confirming that the
drug treatment was selective for PPAR/, or in the
expression of markers of adipocyte differentiation (i.e.,
Pref-1; data not shown), indicating that this latter process
was unaffected. After a 96 h-incubation with GW501516,
cells were exposed to 100 ng/ml LPS for 24 h to induce
inflammation. LPS activates NF-B through TLRs in adi-
pocytes (9,25) and induces insulin resistance (12,26).
When we evaluated the mRNA levels of Mcp-1 and IL-6,
two genes that are under the control of the pro-inflamma-
tory transcription factor NF-B, we observed that LPS
treatment strongly increased the former (22-fold induc-
tion, P  0.001), whereas cells co-incubated with
GW501516 showed a significant reduction (51% reduction,
P  0.01 vs. LPS-exposed cells) (Fig. 2A). Furthermore,
when LPS-exposed cells were co-incubated with 10 mol/l
parthenolide, which specifically inhibits the activation of
NF-B (27), the effect of LPS was suppressed. Treatment
with LPS also led to enhanced IL-6 mRNA levels (4.2-fold
induction, P  0.05), but this increase was blocked in the
presence of GW501516 and parthenolide (Fig. 2B). Like-
wise, incubation with LPS for 24 h caused a 4.2-fold
increase in the levels of IL-6 protein secreted into the
culture media (control 10.5 	 3.7 vs. LPS 55 	 11 ng/ml;
Fig. 2C), whereas pretreatment with GW501516 (56% re-
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FIG. 1. The PPAR/ agonist GW501516 induces Pdk-4 and Cpt-I expression in 3T3-L1 adipocytes. Differentiated adipocytes were incubated in
the presence or in the absence of 0.5 mol/l GW501516 for either 24 h (A) or 96 h (B). Total RNA was isolated and analyzed by RT-PCR. A
representative autoradiogram and the quantification normalized to the Aprt mRNA levels are shown. Data are means  SD of five independent
experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. control.
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duction, P  0.001) and parthenolide (32% reduction, P 
0.05) significantly reduced the secretion of this cytokine.
Several cytokines, including IL-6, stimulate Socs-3 expres-
sion in adipocytes (28), a protein that inhibits insulin
signaling in these cells (29). The elevated levels of mRNA
encoding Socs-3 and the increase in Stat-3 phosphoryla-
tion (Fig. 2D and E) suggested that the increase in IL-6
release caused by LPS treatment might have local actions
(30). Interestingly, GW501516 treatment prevented the
increase in Socs-3 expression and Stat-3 phosphorylation,
a fact that is consistent with the reduction in IL-6 levels
after drug treatment.
PPAR/ activation prevents LPS-mediated NF-B
activation in 3T3-L1 adipocytes. Activation of NF-B
plays a crucial role in IL-6 production in adipocytes, as
demonstrated by the effects of parthenolide. To test
whether GW501516 prevented LPS-induced IL-6 expres-
sion by reducing NF-B activity, we performed EMSA.
NF-B formed three complexes with nuclear proteins
(complexes I–III) (Fig. 3A). The specificity of the three
DNA-binding complexes was assessed in competition ex-
periments by adding an excess of unlabeled NF-B oligo-
nucleotide. NF-B binding activity, mainly of specific
complex II, increased in nuclear extracts from LPS-treated
cells (Fig. 3B). In contrast, in the presence of LPS and the
PPAR/ ligand, the binding activity of NF-B was re-
duced (Fig. 3A). Addition of antibody against the p65
subunit of NF-B completely supershifted complex II,
thereby indicating that this band comprised mainly this
subunit (Fig. 3C).
Reduced PPAR/ activity and enhanced IL-6 expres-
sion in white adipose tissue of an animal model of
obesity and insulin resistance. We hypothesized that a
reduction in PPAR/ activity and the consequent increase
in NF-B activity is responsible, at least in part, for the
enhanced expression of IL-6 in white adipose tissue of
animal models of obesity and insulin resistance. To check
this hypothesis, we evaluated the expression of PPAR/
and its activity in white adipose tissue of ZDF (fa/fa) rats.
Male ZDF and lean rats were killed at 12 weeks of age. By
this age, ZDF rats presented established diabetes com-
pared with lean animals, as demonstrated by increased
plasma levels of glucose (505 	 67 vs. 167 	 37 mg/dl, P 
0.0001), triglycerides (649 	 298 vs. 92 	 31 mg/dl, P 
0.01), nonesterified fatty acids (0.62 	 0.17 vs. 0.26 	 0.09
mEq/l, P  0.01), and insulin (19.3 	 7.9 vs. 10.4 	 2.0
ng/ml, P  0.05). White adipose tissue of ZDF rats showed
a significant reduction in Ppar/ transcripts (50% reduc-
tion, P  0.05) (Fig. 4A). Similarly, the mRNA levels of its
target gene, Pdk4, were also reduced (41%, P  0.05) (Fig.
4B), suggesting that the activity of this PPAR isotype was
reduced. In contrast, the expression of IL-6 was signifi-
cantly enhanced (60%, P  0.05) (Fig. 4C). EMSA showed
that the DNA-binding activity of PPAR was reduced in
white adipose tissue from ZDF rats compared with lean
animals (Fig. 4D). In contrast, NF-B DNA-binding activity
was increased in ZDF rats compared with lean animals
(Fig. 4E). These data suggest that the low-grade chronic
systemic inflammatory associated with the development of
obesity and insulin resistance involves a decreased
PPAR/ activity and the subsequent activation of NF-B.
To clearly demonstrate the involvement of PPAR/ in
the control of NF-B–mediated Il-6 expression in white
adipose tissue, we used the PPAR/-null mice. The ab-
sence of Ppar/ in white adipose tissue (Fig. 5A) was
associated with a reduction in the mRNA levels of Pdk4
(65%, P  0.001) (Fig. 5B) compared with wild-type mice,
whereas IL-6 expression was enhanced (fourfold induc-
tion, P  0.05) (Fig. 5C). In agreement with the enhanced
expression of IL-6 in white adipose tissue of PPAR/-null
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mice, NF-B binding activity was higher in this tissue
compared with that of wild-type mice (Fig. 5D).
PPAR/ regulates ERK1/2 phosphorylation in adipo-
cytes. Next, we attempted to determine the molecular
mechanism by which PPAR/ activation inhibits NF-B.
Although it has been reported that PPAR/ activation
prevents LPS-induced degradation of inhibitor of B
(IB), thus suppressing LPS-induced NF-B in cardiomy-
ocytes (31), we did not observe changes in the protein
levels of this NF-B inhibitor (data not shown) after
GW501516 treatment. On the other hand, ERK1/2 activa-
tion leads to NF-B activation in adipocytes (9). In agree-
ment with this hypothesis, the adipose tissue of ZDF rats
showed enhanced phospho-ERK1/2 levels in the adipose
tissue of ZDF rats compared with lean rats (Fig. 6A). This
observation supports a potential relationship between
activation of ERK1/2 and NF-B. To demonstrate the
involvement of the ERK-MAPK cascade in LPS-induced
NF-B activation in adipocytes, we used U0126, a potent
and specific ERK1/2 inhibitor, which binds to MEK,
thereby inhibiting its catalytic activity and phosphoryla-
tion of ERK1/2. Cells exposed to LPS showed increased
mRNA levels of both Mcp-1 (31-fold induction, P  0.001)
and IL-6 (fourfold induction, P  0.05), whereas co-
incubation with U0126 caused a 35% (P  0.001) and 72%
(P  0.05) reduction in the LPS-mediated induction of
these two genes, respectively (Fig. 6B and C). As a control,
we verified that U0126 treatment inhibited LPS-induced
ERK1/2 activation (Fig. 6D).
Finally, we examined whether the PPAR/ ligand pre-
vented LPS-induced NF-B activation by reducing ERK1/2
phosphorylation in adipocytes. Immunoblotting detection of
total and phosphorylated ERK1/2 (Fig. 6E) revealed that LPS
treatment activated this pathway, whereas in the presence of
the PPAR/ agonist, this pathway was blocked. These
observations suggest that activation of this transcription
factor prevents NF-B activation by inhibiting ERK1/2 phos-
phorylation. To demonstrate that PPAR/ regulates the
ERK1/2 pathway, we explored the expression of this kinase
in adipose tissue of the PPAR/-null mice. These mice
showed enhanced phospho-ERK1/2 protein levels compared
with wild-type mice (Fig. 6F), indicating that PPAR/ regu-
lates this pathway.
DISCUSSION
Obesity, insulin resistance, and type 2 diabetes are closely
associated with low grade of chronic inflammation char-
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acterized by abnormal cytokine production (32). The adi-
pocyte plays a crucial role in this process, because this cell
is a source of cytokines (TNF-, IL-6, and MCP-1), which
are secreted as a result of the activation of several
signaling cascades involved in obesity-induced insulin
resistance (33). A number of studies have implicated
chronic activation of the pro-inflammatory transcription
factor NF-B as one of these signaling pathways (34) that
links inflammation with obesity and type-2 diabetes. For
instance, overexpression of the NF-B activator IKK in
mice results in increased inflammatory cytokine produc-
tion and the onset of diabetes (35). Furthermore, in human
adipose tissue, inhibition of NF-B suppresses the release
of pro-inflammatory cytokines (36). Activation of NF-B
can be achieved by either LPS or FFAs through TLR4 (26).
Several studies have proposed that LPS participates in
initiating the subclinical inflammation observed in obesity
and type 2 diabetes. Thus, circulating LPS levels are higher
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in type 2 diabetic patients than in lean healthy subjects,
and LPS stimulates the secretion of pro-inflammatory
cytokines in human adipocytes (37).
Here, we demonstrate for the first time that PPAR/
activation in adipocytes inhibits LPS-induced cytokine
expression and secretion by preventing NF-B activation.
We (38) and others (31) have previously proposed that
PPAR/ activation inhibits NF-B activation in cardiac
cells either by promoting a protein-protein interaction
between PPAR/ and the p65 subunit of NF-B or by
increasing the expression levels of the NF-B inhibitor
IB. In adipocytes, we did not observe changes either in
the PPAR/-p65 interaction (data not shown) or in IB
protein levels after GW501516 treatment. These observa-
tions suggest that these mechanisms are not involved in
the anti-inflammatory effects of this drug in adipocytes. In
contrast, it has been previously reported that ERK1/2
activation is crucial for the induction of inflammatory
changes in adipocytes (34) and leads to enhanced NF-B
activity (9). In agreement with this role of ERK1/2 in
inflammation in adipocytes, we observed a reduction in
the expression of pro-inflammatory cytokines in these
cells when exposed to LPS in the presence of the MAPK
pathway inhibitor, U0126. This finding is consistent with
previous studies reporting reduced cytokine expression
levels in the presence of this inhibitor in human adipocytes
(9). These data demonstrate that ERK1/2 inhibition pre-
vents NF-B activation and the subsequent increase in
cytokine expression. In addition, we demonstrate that
PPAR/ activation inhibits ERK1/2 phosphorylation,
which is consistent with the reduction in NF-B activation
after GW501516 treatment. Furthermore, the increase in
phospho-ERK1/2 levels observed in white adipose tissue
from PPAR/-null mice is consistent with enhanced
NF-B activity. The involvement of PPAR/ in ERK1/2
regulation has been previously reported in other cell types.
In fact, Burdick et al. (39) recently reported that the
PPAR/ agonist GW0742 reduces phospho-ERK1/2 levels
in human keratinocytes. In addition, phospho-ERK1/2 lev-
els are higher in the skin of PPAR/-null mice treated
with 12-O-tetradecanoylphorbol-13-acetate than in the skin
of wild-type animals (40). Overall, these data confirm that
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PPAR/ regulates phospho-ERK1/2 levels in several tis-
sues. Additional studies are required to elucidate the
molecular mechanism by which PPAR/ controls ERK-
1/2 activation.
Here, we demonstrate a correlation between en-
hanced ERK1/2 phosphorylation and NF-B activation
in the white adipose tissue of a genetic model of obesity
and diabetes, the ZDF rat. Given the low level of Ppar/
in the white adipose tissue of these animals, we hypoth-
esize that a decrease in the expression of this nuclear
receptor is one of the underlying mechanisms of this
correlation. On the basis of our data, we propose that in
this animal model, PPAR/ downregulation leads to
enhanced ERK1/2 phosphorylation, which in turn acti-
vates NF-B in white adipose tissue and, as a result,
induces pro-inflammatory cytokine expression. This hy-
pothesis is supported by the observation that white
adipose tissue from the PPAR/-null mice shows in-
creased phospho-ERK1/2 levels and NF-B activity and
higher expression of IL-6 compared with wild-type mice.
Although further studies are required to demonstrate
this relationship between PPAR/ and NF-B in white
adipose tissue, our data provide further insight into the
role of obesity-related insulin resistance and low-grade
inflammation.
In summary, on the basis of our findings in adipocytes,
we propose that PPAR/ activation prevents LPS-in-
duced NF-B activation via ERK1/2, thereby reducing the
production of pro-inflammatory cytokines involved in the
development of insulin resistance. This action of PPAR/
may contribute to preventing obesity-induced insulin
resistance.
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